Bioniche Life Sciences Inc. to Provide an Update on Vaccine Manufacturing Centre Validation
BELLEVILLE, ON, June 27, 2013 /PRNewswire/ – Bioniche Life Sciences Inc. (TSX:
BNC) (ASX: BNC) today announced that it will be hosting a:
Conference Call & Audio Webcast
Tuesday, July 9, 2013
6:00 p.m. ET
Company representatives will provide an update on GMP validation of its
Animal Health and Food Safety Vaccine Manufacturing Centre in
To participate in the conference call from North America, call (888)
231-8191 (conference ID: 13113047).
To participate in the conference call from Australia, call 1-800-287-011
(conference ID: 13113047).
A listen-only audio webcast will be available at:
A replay of the conference call will be available until July 16, 2013 at
midnight by calling 1-855-859-2056 (passcode: 13113047).
The webcast will be available for replay using the above link until July
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and Food
Safety. The Company’s primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder
For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company’s current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company’s ongoing quarterly and
SOURCE Bioniche Life Sciences Inc.